Fisher Wallace Laboratories, Inc.
Regulation Crowdfunding offering on DealMaker Securities · Form C filed October 7, 2026 · Brooklyn, Ohio
Fisher Wallace Laboratories, Inc. develops wearable transcranial alternating current stimulation technology for neuropsychiatric and cognitive disorders. The company stopped selling its Version 1.0 device in April 2023 and is seeking FDA clearance for a Version 2.0 device that remains in development.
Profile details below were extracted automatically from the issuer's filing documents. Figures in the financial table come directly from the SEC's structured Form C data.
Offering terms
- Security
- Common Stock
- Maximum
- $3,945,730.50
- Price
- $11.38 per unit
- Pricing method
- Not stated
- Deadline
- November 19, 2026
- Oversubscriptions
- Accepted
- Intermediary
- DEALMAKER SECURITIES LLC
Broker-dealer, SEC file 008-70756 - Intermediary fee
- Up to 8.5%
- Intermediary equity
- None
Financials as filed
| Item | Most recent FY | Prior FY |
|---|---|---|
| Revenue | $34,261 | $47,412 |
| Cost of goods sold | $5,049 | $3,012 |
| Net income (loss) | -$1,447,538 | -$1,579,900 |
| Total assets | $144,634 | $154,382 |
| Cash and equivalents | $48,142 | $41,626 |
| Accounts receivable | $0 | $0 |
| Short-term debt | $591,311 | $596,721 |
| Long-term debt | $693,612 | $925,582 |
| Taxes paid | $0 | $0 |
Two fiscal years as reported on the Form C cover sheet. 2 employees. Offered in 64 states.
Use of proceeds
At the $3,945,731 maximum total proceeds, $473,818 goes to intermediary, activation and investor processing fees, leaving $3,471,913 in net proceeds, of which $1,159,770 goes to clinical research, $773,179 each to manufacturing and product development, $572,490 to operations, and $193,295 to regulatory consulting and legal fees.
Valuation
Pre-money valuation: Not stated. Valuation cap, discount and interest rate for this offering: Not stated. Pricing basis: $11.38 per Class B share, or $11.78 including the 3.5% investor processing fee, which the filing says was determined arbitrarily. Separately, the February 2025 Reg CF convertible notes bear 10% simple interest and convert at a 20% discount to the next financing price.
Prior raises
Feb 2023 Reg CF $1,192,627; Mar 2023 Reg A+ $468,754; Nov 2023 Reg CF $532,202; Jan 2024 Reg CF $469,069; Mar 2024 Reg CF $405,904; June 2024 Reg CF $237,729; Sept 2024 Reg CF $281,257.67; Dec 2024 Reg CF $217,433.65; Feb 2025 Reg CF convertible notes $203,314.37 (including fee); May 2025 Reg D 506(c) $92,820 (tentative); Nov 2025 Reg CF $228,289.74; Dec 2025 Reg CF $195,231; Jan 2026 Reg CF $130,120.23; May 2026 Reg CF amount not stated (text cut off).
Financial statements
Described as audited. The MD&A refers to audited consolidated financial statements and to an independent auditor's going concern paragraph; the auditor's name and city are not stated.